EC- press serviceEUBiopharmaceutical sector welcomes EU Biotech ActThe European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who … more ➔
John Kiel - wikipediaM&ASobi strengthens gout pipeline with Arthrosi acquisitionSobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing … more ➔
Sanofimultiple sclerosisSanofi facing tolebrutinib setback in MSSanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS. more ➔
FIDA Biosystems ApSFinancingEifo and Fsg back Fida Biosystems with €5m investmentFida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug d … more ➔
VFAClinical studiesGerman pharma association publishes clinical trial rankingThe German pharmaceutical association vfa has updated its ranking of the best locations for industry-sponsored clinical trials. In Europe, Spain retained its top position in 2024, followed by Australia, … more ➔
Van Overeem Nuclear BVCancer radiopharmaceuticalsRadioMedix expands thorium-228 supply for 212PbRadiopharmaceuticals specialist RadioMedix Inc has secured five-year Thorium-228 supply from Van Overeem, strengthening 212Pb production and Targeted Alpha Therapy pipeline development. more ➔
ObesityZealand pays Chinese OTR US$30m upfront to expand obesity pipelineDanish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal. more ➔
Momoneymoproblemz - wikimediaObesityLilly‘s retatrutide delivers record weight lossLilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide. more ➔
San Antonio Breast Cancer SymposiumBreast CancerPfizer presents data for Tukysa in HER2-positive breast cancerPfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety. Data were shown at the 2025 San Antonio Breast … more ➔
PubChemBreast cancerRoche presents details on breast cancer pill giredestrantRoche has unveiled detailed data for its oral selective estrogen receptor degrader (SERD), giredestrant, at the 2025 San Antonio Breast Cancer Symposium. more ➔
EC- press service
John Kiel - wikipedia
Sanofi
FIDA Biosystems ApS
VFA
Van Overeem Nuclear BV
Momoneymoproblemz - wikimedia
San Antonio Breast Cancer Symposium
PubChem